학술논문
Best response (BR) may be predictive of progression-free survival (PFS) in patients with metastatic renal cell cancer (mRCC) treated with tyrosine kinase inhibitors (TKI) in first line
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
18790852